Barcelona, Spain

Monserrat Simon Fornell

This inventor holds 1 USPTO granted patent. Top assignee: Medichem, S.a.. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Monserrat Simon Fornell. Retrieved from https://idiyas.com/inventor/monserrat-simon-fornell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 72(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Monserrat Simon Fornell: Innovator in Acetylcholinesterase Inhibitors

Introduction

Monserrat Simon Fornell is a notable inventor based in Barcelona, Spain. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target acetylcholinesterase. Her work is crucial in the advancement of treatments for various neurological conditions.

Latest Patents

Monserrat holds a patent for polycyclic aminopyridine compounds which are acetylcholinesterase inhibitors. This innovation represents a step forward in the search for effective therapies for diseases related to acetylcholine dysfunction.

Career Highlights

Monserrat is currently employed at Medichem, S.A., a company known for its commitment to pharmaceutical development. Her role involves extensive research and development, focusing on innovative solutions in the medicinal chemistry sector.

Collaborations

Monserrat has collaborated with talented coworkers, including Pelayo Camps Garcia and Diego Munoz-Torrero Lopez-Ibarra. These partnerships enhance the research environment and contribute to the success of their projects.

Conclusion

Monserrat Simon Fornell is a pioneering inventor whose work in acetylcholinesterase inhibitors is making a significant impact in the field of medicinal chemistry. Her contributions are vital for the development of new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…